AFP and hepatocellular carcinoma: Prothrombin induced by vitamin K absence‐II (PIVKA‐II) and Lens culinaris‐agglutinin‐reactive fraction of AFP (AFP‐L3) have both been approved by FDA for risk stratification but not surveillance of hepatocellular carcinoma in the USA.13